Proathlete Wealth Management
GSK icon

Proathlete Wealth Management’s GSK GSK Stock Holding History

Proathlete Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.34K Buy
194
+115
+146% +$5.87K ﹤0.01% 359
2026
Q2 		$4.14K Hold
79
– – ﹤0.01% 178
2026
Q1 		$4.36K Sell
79
-68
-46% -$3.68K ﹤0.01% 177
2025
Q4 		$7.21K Buy
+147
New +$6.86K ﹤0.01% 172

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
JTC Employer Solutions Trustee
JTC Employer Solutions Trustee St Helier, Jersey $1.16B AUM 24.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $46.6B AUM 32.12% 1-Year Est. Return

Proathlete Wealth Management's GSK Position: Q3 2026 in Review

Proathlete Wealth Management increased its GSK (GSK) stake by 146% in Q3 2026, buying an estimated $5.87K and bringing the position to 194 shares worth $9.34K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

Proathlete Wealth Management first reported a position in GSK in Q4 2025 and has held it in 4 quarters since. 854 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Proathlete Wealth Management held 194 shares of GSK worth $9.34K as of Q3 2026.
  • Proathlete Wealth Management bought 115 GSK shares in Q3 2026, an estimated $5.87K.
  • GSK made up ﹤0.01% of Proathlete Wealth Management's portfolio in Q3 2026, its #359 holding.
  • Proathlete Wealth Management first reported a position in GSK in Q4 2025 and has held it in 4 quarters since.
  • 854 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Proathlete Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.